-
公开(公告)号：KR100477326B1
公开(公告)日：2005-03-21
申请号：KR1020010020813
申请日：2001-04-18
Applicant: 한국과학기술연구원
IPC: C07K16/18
Abstract: 본 발명은 N-글리코시드 결합을 분해할 수 있는 촉매항체와 이를 코딩하는 DNA 분자를 제공하며, 당결합을 특이적으로 인식하고 절단할 수 있는 이러한 촉매항체는 여러 가지 복잡한 당분자를 쉽게 다룰 수 있는 수단이 되고, 인공 촉매의 기작에 관한 연구는 자연의 중요한 전이 반응 (transfer reaction)인 당의 형성과 분해과정에 작용하는 중요한 인자를 발견할 수 있는 기회를 제공해 줄 수 있으며, N-글리코시드 결합이 생체내의 중요한 대사경로에 관여하는 결합이라면 생체내의 치료제로서 사용할 수 있는 유용한 물질을 제공할 수 있다.
-
公开(公告)号：KR1020020080939A
公开(公告)日：2002-10-26
申请号：KR1020010020813
申请日：2001-04-18
Applicant: 한국과학기술연구원
IPC: C07K16/18
CPC classification number: C07K16/18 , C07K2317/565
Abstract: PURPOSE: Catalytic antibodies with N-glycosidase activity are provided, therefore various complex sugar molecules can be easily treated, and they can be useful in studies on the formation and decomposition of sugars. CONSTITUTION: The catalytic antibodies with N-glycosidase activity have a light chain represented by the nucleotide sequence of SEQ ID NO: 1 and a heavy chain represented by the nucleotide sequence of SEQ ID NO: 2 and the light chain and the heavy chain are connected by a linker. A DNA molecule encoding a single chain catalytic antibody comprises the catalytic antibody with N-glycosidase activity consisting of the light chain represented by the nucleotide sequence of SEQ ID NO: 1 and the heavy chain represented by the nucleotide sequence of SEQ ID NO: 2, and the linker represented by the nucleotide sequence of SEQ ID NO: 3.
Abstract translation: 目的：提供具有N-糖苷酶活性的催化抗体，因此可以容易地处理各种复杂的糖分子，并且它们可用于研究糖的形成和分解。 构成：具有N-糖苷酶活性的催化抗体具有由SEQ ID NO：1的核苷酸序列表示的轻链和由SEQ ID NO：2的核苷酸序列表示的重链，轻链和重链连接 通过链接器。 编码单链催化抗体的DNA分子包含具有由SEQ ID NO：1的核苷酸序列表示的轻链和由SEQ ID NO：2的核苷酸序列表示的重链的N-糖苷酶活性的催化抗体， 和由SEQ ID NO：3的核苷酸序列表示的接头。
-
Patent Agency Ranking
公开(公告)号：KR100341827B1
公开(公告)日：2002-06-26
申请号：KR1020000004480
申请日：2000-01-29
Applicant: 한국과학기술연구원
IPC: C07K16/00
Abstract: 본발명은 시험관적 면역법을 사용하여 아미노-RNA에 대한 항체 및 이를 제조하는 방법을 제공하여, 일반 RNA로 생체면역법을 이용하여 생성할 수 없는 RNA에 대한 항체를 비교적 안정한 아미노-RNA로서 시험관내 면역법으로 생산할 수 있으며, 또한 얻어진 항체는 자가면역질환의 특정 자가항체와 특이적이고 강하게 결합하여 자기면역질환을 방지할 수 있어 자기면역질환 치료제로 유용하고, 또한 아미노-RNA를 생체내로 투여하여 이에 대한 항체의 생성을 유발할 수 있어 자가면역질환에 대한 백신제로 개발가능하다.
-
公开(公告)号：KR100464926B1
公开(公告)日：2005-01-05
申请号：KR1020010056800
申请日：2001-09-14
Applicant: 한국과학기술연구원
IPC: C07K16/18
Abstract: PURPOSE: Antibodies specifically binding to the N-terminal of HIV gp 41 are provided, thereby function of gp41 which is essential for the infection of HIV can be inhibited, so that it can be useful for prevention and treatment of HIV. CONSTITUTION: The antibodies which are specifically binding to the N-terminal of HIV gp 41, are capable of recognizing gp 41-ex(extracellular domain), and inhibit function of gp 41 are provided, wherein the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 1 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 2; the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 3 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 4; the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 5 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 6; and the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 7 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 8.
Abstract translation: 目的：提供特异性结合于HIV gp41 N末端的抗体，从而可以抑制对HIV感染至关重要的gp41的功能，从而可用于HIV的预防和治疗。 构成：特异性结合于HIV gp 41 N末端的抗体能够识别gp 41-ex（胞外结构域），并且提供gp 41的抑制功能，其中抗体的重链具有氨基酸 SEQ ID NO：1的氨基酸序列和抗体的轻链具有SEQ ID NO：2的氨基酸序列; 抗体的重链具有SEQ ID NO：3的氨基酸序列，抗体的轻链具有SEQ ID NO：4的氨基酸序列; 抗体的重链具有SEQ ID NO：5的氨基酸序列，抗体的轻链具有SEQ ID NO：6的氨基酸序列; 并且抗体的重链具有SEQ ID NO：7的氨基酸序列，并且抗体的轻链具有SEQ ID NO：8的氨基酸序列。
-
公开(公告)号：KR1020030024004A
公开(公告)日：2003-03-26
申请号：KR1020010056800
申请日：2001-09-14
Applicant: 한국과학기술연구원
IPC: C07K16/18
CPC classification number: C07K16/1045 , A61K39/21
Abstract: PURPOSE: Antibodies specifically binding to the N-terminal of HIV gp 41 are provided, thereby function of gp41 which is essential for the infection of HIV can be inhibited, so that it can be useful for prevention and treatment of HIV. CONSTITUTION: The antibodies which are specifically binding to the N-terminal of HIV gp 41, are capable of recognizing gp 41-ex(extracellular domain), and inhibit function of gp 41 are provided, wherein the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 1 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 2; the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 3 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 4; the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 5 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 6; and the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 7 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 8.
Abstract translation: 目的：提供与HIV gp 41的N-末端特异性结合的抗体，因此可以抑制对HIV感染必不可少的gp41的功能，因此可用于预防和治疗HIV。 构成：与HIV gp41的N-末端特异性结合的抗体能够识别gp 41-ex（细胞外结构域），并提供抑制gp41功能，其中抗体的重链具有氨基 SEQ ID NO：1的酸序列和抗体的轻链具有SEQ ID NO：2的氨基酸序列; 抗体的重链具有SEQ ID NO：3的氨基酸序列，抗体的轻链具有SEQ ID NO：4的氨基酸序列; 抗体的重链具有SEQ ID NO：5的氨基酸序列，抗体的轻链具有SEQ ID NO：6的氨基酸序列; 抗体的重链具有SEQ ID NO：7的氨基酸序列，抗体的轻链具有SEQ ID NO：8的氨基酸序列。
-
公开(公告)号：KR1020010076990A
公开(公告)日：2001-08-17
申请号：KR1020000004480
申请日：2000-01-29
Applicant: 한국과학기술연구원
IPC: C07K16/00
CPC classification number: C07K16/40 , C07K16/286 , C07K2317/56
Abstract: PURPOSE: An antibody for amino-RNA and a producing method thereof are provided, thereby the antibody can be easily produced, and it can be used in treatment of self-immunity disease. CONSTITUTION: The antibody for amino-RNA comprises VH of SEQ ID NO: 1 and VL of SEQ ID NO: 2, in which the amino-RNA specifically binds with a receptor of acetylcholine esterase. The method for producing the antibody for amino-RNA comprises the steps of: producing amino-RNA by substituting nucleotides of RNA during transcription from DNA of MG self-antibody to RNA; collecting a spleen from a mouse; carrying out in vitro immunization technique by incubating the spleen cells in a medium containing the amino-RNA for 3 days; fusing the immunized spleen cells with SP2/o-Ag14 and PEG1500; incubating them to produce hybridoma cells; and selecting hybridoma cells capable of producing antibody binding with amino-RNA.
Abstract translation: 目的：提供了用于氨基-RNA的抗体及其制备方法，由此能够容易地制备抗体，可以用于自身免疫性疾病的治疗。 构成：氨基-RNA抗体包含SEQ ID NO：1的VH和SEQ ID NO：2的VL，其中氨基-RNA与乙酰胆碱酯酶的受体特异性结合。 制备氨基-RNA抗体的方法包括以下步骤：通过在从MG自身的DNA转录到RNA的转录过程中用RNA取代RNA来产生氨基RNA; 从小鼠收集脾脏; 通过将脾细胞在含有氨基-RNA的培养基中培养3天进行体外免疫技术; 将免疫的脾细胞与SP2 / o-Ag14和PEG1500融合; 培养它们以产生杂交瘤细胞; 并选择能够产生与氨基-RNA结合的抗体的杂交瘤细胞。
-
公开(公告)号：KR1020010076994A
公开(公告)日：2001-08-17
申请号：KR1020000004484
申请日：2000-01-29
Applicant: 한국과학기술연구원
IPC: C07H21/00
Abstract: PURPOSE: Provided is DNA sequence that codes variable region of an antibody having enzymatic activity degrading glycosidic bond. And its expression method is also provided. CONSTITUTION: A DNA sequence coding variable region of an antibody having enzymatic activity degrading glycosidic bond is as follows: DNA sequence represented by sequence ID. No. 1 coding VH chain of antibody for glycosidase, 4f4r; DNA sequence represented by sequence ID. No. 3 coding VH chain of antibody for glycosidase, 6h4h; DNA sequence represented by sequence ID. No. 5 coding VH chain of antibody for glycosidase, Ab2l; DNA sequence represented by sequence ID. No. 7 coding antibody for glycosidase, 4f4r; DNA sequence represented by sequence ID. No. 9 coding VL chain of antibody for glycosidase, 6h4h; or DNA sequence represented by sequence ID. No. 11 coding VL chain of antibody for glycosidase, Ab2l. Wherein, all sequences are described as in the description. The antibody is prepared by expressing a fusion protein of VH and VL in an eukaryote cell or bacteria.
Abstract translation: 目的：提供编码具有酶活性降解糖苷键的抗体的可变区的DNA序列。 并提供其表达方法。 构成：具有酶活性降解糖苷键的抗体的编码可变区的DNA序列如下：由序列ID表示的DNA序列。 1号编码糖苷酶抗体的VH链，4f4r; 由序列ID表示的DNA序列。 3号编码糖苷酶抗体VH链，6h4h; 由序列ID表示的DNA序列。 编码糖基化抗体的第5号VH链，Ab2l; 由序列ID表示的DNA序列。 糖苷酶7号编码抗体，4f4r; 由序列ID表示的DNA序列。 9号编码糖苷酶抗体VL链，6h4h; 或由序列ID表示的DNA序列。 11号编码糖苷酶抗体的VL链，Ab2l。 其中所有序列如描述中所述。 通过在真核细胞或细菌中表达VH和VL的融合蛋白来制备抗体。
-
-
-
-
-
-
Search Results
7
records
(took 0.019 seconds)
